デチロシネート・α-チューブリンは,心不全におけるミトコンドリア機能障害とダイアストリック障害を媒介する

Shunsuke Miura¹, Tomofumi Misaka^1,2, Toranosuke Sekine¹

¹Department of Cardiovascular Medicine, Fukushima Medical University, Fukushima, Japan.

FEBS letters

|August 29, 2025

まとめ

デチロシネートアルファチューブリンは,心不全でミトコンドリア機能障害とミトファギーの障害を引き起こします. このメカニズムをターゲットにすると,HFpEFの新たな治療戦略が生まれます.

科学分野:

心血管生物学
分子細胞生物学
ミトコンドリア医学

背景:

放出分数保存 (HFpEF) による心不全は,静脈動脈機能不全によって特徴づけられる.
HFpEFの背後にある正確な分子メカニズムは,まだ完全に理解されていません.
ミトコンドリア機能障害とミトファギーの障害は,HFpEFの病原性に関与しています.

研究の目的:

HFpEFにおけるオキシトシン化されたアルファチューブリンの役割を調査する.
HFpEFにおけるアルファチューブリンオキシトシン化,ミトコンドリア機能,ミトファギーの間の分子関連を解明する.
HFpEFの潜在的治療標的を特定する.

主な方法:

SAUNA誘発のHFpEFマウスモデルを使用した.
VASH1過剰発現とチューブリンチロシンリガースノックアウトによるH9c2心筋細胞実験を用いた.
ミトコンドリア呼吸,ミトファジーマーカー (パーキン募集,VDAC1ユビキチネーション),心臓機能の評価

主要な成果:

HFpEFモデルでは,バソヒビン-1 (VASH1) 発現が増加し,オイキソシン化アルファチューブリンが増加した.
アルファチューブリンが増加すると,ミトコンドリアの呼吸が低下し,ミトファギーが抑制され,パーキンの募集が低下した.
心臓特異的なVASH1発現は,腹動機能障害とミトコンドリア活性低下を含む,HFpEFのようなフェノタイプを誘発した.

結論:

アルファチューブリン結合は,HFpEFにおけるミトコンドリア機能障害とミトファギーの障害の主要な要因である.
VASH1- 脱チロシン化アルファチューブリン軸は,HFpEFの病原性における新しい経路を表しています.
アルファ・チューブリン・オキシトシネーションをターゲットにすることで,HFpEFに対する潜在的な治療戦略が提供されます.

キーワード:

発射分子が保存された心不全ミトコンドリアミトファジーバソヒビン 1 α-チューブリンオキシトシネーション

さらに関連する動画

10:30

Analysis of Tubular Membrane Networks in Cardiac Myocytes from Atria and Ventricles

Published on: October 15, 2014

20.7K

09:20

Author Spotlight: Exploring Mitochondrial Function and Chemical Toxicity Using Drosophila melanogaster

Published on: November 10, 2023

1.1K

関連する概念動画

01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...

01:17

Pathophysiology of Heart Failure

1.8K

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...

1.8K

01:22

Heart Failure Drugs: Diuretics

483

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...

483

01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...

01:26

Heart Failure Drugs: Inotropic Agents

717

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...

717

01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...

関連する実験動画